Methods and compositions for treating and preventing viral infections
AssigneeEnterin, Inc.
InventorMichael Zasloff
Life of this patent
Estimating the term…
Abstract
A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving the systemic antiviral effect.
Claims35
An in vivo method of treating or preventing a viral infection in a mammal comprising administering a composition comprising:
- (a) a pharmaceutically acceptable grade of squalamine or a pharmaceutically acceptable salt or derivative thereof in an amount sufficient to produce an antiviral effect, and
- (b) at least one pharmaceutically acceptable carrier,
- wherein the viral infection is caused by a virus selected from the group consisting of Yellow Fever, Eastern Equine Encephalitis virus, Human Immunodeficiency virus (HIV), “African Swine Fever Viruses,” Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Astroviridae, Baculoviridae, Bimaviridae, Bimaviridae, Bunyaviridae, Caliciviridae, Caulimoviridae, Circoviridae, Coronaviridae, Cystoviridae, EBV, Deltaviridae, Filviridae, Filoviridae, Flaviviridae, Iridoviridae, Mononegavirus, Myoviridae, Papiloma virus, Papovaviridae, Paramyxoviridae, Prions, Parvoviridae, Phycodnaviridae, Poxviridae, Potyviridae, Reoviridae, Retroviridae, Rhabdoviridae, Tectiviridae, Togaviridae, pox, papilloma, corona, influenza, sendai virus (SeV), sindbis virus (SINV), vaccinia viruses, West Nile, Hanta, viruses which cause the common cold, and any combination thereof, and
- wherein the composition is systemically administered intravenously, subcutaneously, intramuscularly, orally, or by inhalation.
An in vivo method of treating or preventing a viral infection in a mammal comprising administering a composition comprising:
- (a) a pharmaceutically acceptable grade of squalamine or a pharmaceutically acceptable salt or derivative thereof in an amount sufficient to produce an antiviral effect, and
- (b) at least one pharmaceutically acceptable carrier,
- wherein the viral infection is caused by a virus selected from the group consisting of:
- (i) a Mononegavirus which is Paramyxoviridae, Morbillivirus, or Rhabdoviridae;
- (ii) a Picomaviridae virus which is Rhinovirus or Poliovirus;
- (iii) a Poxviridae virus which is Smallpox or Vaccinia;
- (iv) a Reoviridae virus which is Rotavirus;
- (v) a Retroviridae virus which is HTLV-I, HTLV-II, or Lentivirus;
- (vi) a Togaviridae virus which is Rubivirus;
- and
- (vii) any combination thereof.
A method of treating or preventing a chronic disease suspected to be of viral origin, wherein the condition is selected from the group consisting of multiple sclerosis, Type I diabetes, Type II diabetes, atherosclerosis, cardiomyopathies, Kawaski disease, and aplastic anemia, and wherein the method comprises administering a composition comprising:
- (a) a pharmaceutically acceptable grade of squalamine or a pharmaceutically acceptable salt or derivative thereof in an amount sufficient to produce an antiviral effect, and
- (b) at least one pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.